Table 1

Baseline patient demographic and disease characteristics (full analysis set)

Demographic variableLBEC0101
Age, years52.8±11.655.5±10.954.1±11.3
Sex, female150 (81.1)166 (88.8)316 (84.9)
Weight, kg58.1±12.256.3±10.157.2±11.2
Functional status in RA
 I31 (16.8)34 (18.2)65 (17.5)
 II121 (65.4)121 (64.7)242 (65.1)
 III33 (17.8)32 (17.1)65 (17.5)
Duration since first RA diagnosis, years7.6±7.67.8±7.67.7±7.6
Rheumatoid factor test result, positive144 (77.8)144 (77.0)288 (77.4)
Tender joint count from 68 joints17.5±±10.817.8±10.7
Tender joint count from 28 joints11.0±6.011.7±5.911.3±5.9
Swollen joint count from 66 joints13.4±7.513.7±7.513.6±7.5
Swollen joint count from 28 joints9.2±4.69.8±5.19.5±4.8
ESR, mm/hour49.2±23.851.5±23.850.4±23.8
CRP, mg/dL1.63±1.81.7±2.11.7±1.9
MTX dose, mg/week11.3±2.911.1±3.011.2±3.0
Patients who used biologics previously and corticosteroids at baseline, n (%)
 Previous use of biologics31 (16.8)29 (15.5)60 (16.1)
 Baseline corticosteroids130 (70.3)119 (63.6)249 (66.9)
  • Data are presented as mean±SD or n (%).

  • CRP, C reactive protein; DAS28-ESR, disease activity score in 28 joints based on erythrocyte sedimentation rate; ESR, erythrocyte sedimentation rate; ETN-RP, etanercept reference product; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; PhGADA, physician’s global assessment of disease activity; PtAP, patient’s assessment of arthritis pain; PtGADA, patient’s global assessment of disease activity; RA, rheumatoid arthritis.